As scientific researchers continue to investigate the complexities of the microbiome-gut brain communication highway, our mission for the 3rd Microbiome Movement - Gut-Brain Axis Summit is simple: Unite pioneering industry and academic researchers to establish the mechanistic pathways contributing to neurological disorder manifestation, overcome the scientific and translational challenges of working in the gut-brain setting and capitalize on this therapeutic opportunity.
Our conversations have highlighted that there are critical areas of basic science that need addressing including demonstrating the causality of microbiome gut-brain interactions, translating microbiome science into therapeutic or nutritional targets through pre-clinical models and harnessing clinical experience to inform in-human study design to accelerate product development.
If you're keen to make sense of microbiome gut-brain science and its potential applications in understanding neurological disorder etiology, identifying microbial biomarkers for patient stratification and development of innovative symptom management strategies, join your scientifically-driven peers from the pharmaceutical, nutritional and academic community to discover and clinically validate microbiome gut-brain axis pathways to transform treatment strategies for patients with neurological disorders.
Group discounts, start-up, academic and early booking rates are available. Please visit the website for full pricing information.
Conference + 1 Workshop (Industry): USD 2898.0,
Conference Only (Industry): USD 2399.0,
Workshop (Industry): USD 599.0,
Conference + 1 Workshop (Academic And Start-Up): USD 1998.0,
Conference Only (Academic And Start-Up): USD 1699.0,
Workshop (Academic And Start-Up): USD 399.0
Speakers: Christopher Missling, President And CEO, Anavex Life Sciences, David Donabedian, Co-Founder, CEO And Director, Axial Biotherapeutics, Melanie Maya Kaelberer, Post-Doctoral Fellow Bohorquez Lab, Duke University, Timothy Buie, Attending Gastroenterologist, Boston Children's Hospital, Michael Zasloff, Founder, CEO And Chairman, Enterin, Inc, Zain Kassam, Chief Medical Officer, Finch Therapeutics, Philip Strandwitz, CEO, Holobiome, Peter Nara, Chief Scientific Officer And Founder, Keystone Bio, Alessio Fasano, Professor And Director Mucosal Immunology And Biology, Research Center Massachusetts General Hospital, Stephen Skolnick, Research Technologist, Massachusetts Institute of Technology, Rishab Shyam, Executive Director, PureTech Health, Ali Keshavarzian, Professor And Gastroenterologist, Rush University Medical Center, Frank Middleton, Associate Professor, SUNY Upstate Medical University, Nader Yaghoubi, Co-Founder And CEO, Symbiotix Biotherapies Inc, Nicole Polinski, Senior Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research, Valerie Taylor, Department Chair of Psychiatry And Scientist, University of Calgary And Hotchkiss Brain Institute, Jing Lu, Research Professional, University of Chicago, Ai-Ling Lin, Associate Professor, University of Kentucky